Evidence map›Paper›PMID 40636136›Full record

ArticleiLIVER2022

Ascorbic acid ameliorates isoniazid-rifampicin-induced hepatocellular damage in rats.

Shubham Patel, Aman Chaturvedi, Nazneen Dubey, Abhishek Shrivastava, Aditya Ganeshpurkar

Erratum issuedAbstract read
In one paragraph

Article in iLIVER, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Shubham PatelShri Ram Institute of Technology-Pharmacy, Jabalpur, India.
Aman ChaturvediShri Ram Institute of Technology-Pharmacy, Jabalpur, India.
Nazneen DubeyShri Ram Institute of Technology-Pharmacy, Jabalpur, India.
Abhishek ShrivastavaShri Ram Institute of Technology-Pharmacy, Jabalpur, India.
Aditya GaneshpurkarShri Ram Institute of Technology-Pharmacy, Jabalpur, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Phyto-constituents are widely recognized for hepatoprotective effects. Ascorbic acid is extensively studied for the radical scavenging effect. The objective of the present study was to evaluate the hepatoprotective effect of ascorbic acid against isoniazid and rifampicin-induced liver damage in rats. Methods: Wistar rats were used in the present study. Hepato-cellular damage was produced by the administration of isoniazid (100 mg/kg) and rifampicin (100 mg/kg) for 21 days. Ascorbic acid was administered in the dose of 50, 100, and 200 mg/kg body weight. At the end of the study, blood was collected and biochemical studies were performed to determine antioxidant status. Results: Ascorbic acid administration (50, 100, and 200 mg/kg body weight) caused restoration of serum glutamic oxaloacetic transaminase, serum glutamic-pyruvic transaminase, and serum alkaline phosphatase. The level of superoxide dismutase and catalase were also restored due to the administration of ascorbic acid. There was a decrement in the expression of tumor necrosis factor-α, interleukin-1β, interleukin-6, malondialdehyde and nitric oxide. Conclusion: The outcome of the study established ascorbic acid as a notable hepatoprotective effect. The radical scavenging and cytokine suppression effect is the possible mechanism associated with the hepatoprotective effect of ascorbic acid.

Indexed as

AntitubercularAscorbic acidCytokinesLiverPeroxidationToxicity

Identifiers

PMID40636136
PMCPMC12212586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.